Monogenic and polygenic determinants of sarcoma risk: an international genetic study
Mandy L. Ballinger(Garvan Institute of Medical Research), David M. Thomas(Chris O’Brien Lifehouse), Beatrice Seddon(Helios Klinikum Emil von Behring), Paul A. James(The Royal Melbourne Hospital), Ola Myklebost(Oslo University Hospital), Joshua D. Schiffman(University of Utah), Rajiv Sarin(Advanced Centre for Treatment, Research and Education in Cancer), Andrew S. Brohl(Moffitt Cancer Center), Ian Campbell(The University of Melbourne), Jin Hee Ahn(Asan Medical Center), Jean‐Yves Blay(Centre Léon Bérard), David L. Goode(University of Melbourne), Victoria Beshay(Peter MacCallum Cancer Centre), Sung‐Min Ahn(Konkuk University), Ian Judson(Institute of Cancer Research), Mary‐Anne Young(University of Melbourne), R. Lor Randall, Eva W. Stratford(Oslo University Hospital), Séan O’Donoghue(Commonwealth Scientific and Industrial Research Organisation), Eveline Niedermayr(Peter MacCallum Cancer Centre), Robert G. Maki(Memorial Sloan Kettering Cancer Center), Isabelle Ray‐Coquard(Centre Léon Bérard), Arcadi Cipponi(The Kinghorn Cancer Centre), Ajay Puri(Tata Memorial Hospital), Gillian S. Dite(University of Melbourne), Jeong Eun Kim(Asan Medical Center), Susanne Lorenz(Oslo University Hospital), Gillian Mitchell(Peter MacCallum Cancer Centre), Sue Shanley(Peter MacCallum Cancer Centre)
Cited by 213
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k